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Genetic modification of adenoviral capsid proteins is a commonly used strategy for 
broadening the tissue tropism of adenoviral gene therapy vectors and thus increasing their 
therapeutic potential. To accurately measure the effects on cell tropism of genetically 
modified adenovirus vectors, new highly sensitive detection and tracking techniques are 
required that can be easily adapted to the wide array of pre-existing gene therapy vectors 
without the need for further genetic modification. Quantum dots are nano-sized fluorescent 
particles with high quantum yields and extended photo-stability, making them excellent 
labels for single particle detection. We have utilised streptavidin-conjugated quantum dot 
technology to detect the binding of biotinylated human adenovirus and adenoviral gene 
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therapy vectors to target cells. We demonstrate that this technique has no impact on virus 
fitness or specificity whilst enabling the detection of virus binding events and internalisation 
using a variety of imaging and cytometry techniques. Furthermore, Qdot labelling of 
adenovirus is at least 10-fold more sensitive than conventional organic fluorophore labelling 
techniques such as genetic incorporation of eGFP into the viral capsid. This method has 
been applied to characterise the tropism of different adenovirus species and tropism-
modified adenoviral gene therapy vectors and will provide a valuable new tool for studying 
adenoviral receptor interaction and cell entry. 
 
The seven species of human adenovirus (A-G) comprise at least 52 serotypes which are 
responsible for a range of usually mild and self-limiting infections. Most species A, C, E, F 
and G human adenoviruses (Ad) and some from species D can bind to cells via interaction 
of the fibre knob domain with the coxsackie and adenovirus receptor (CAR).
[1-3]
 Species C 
adenoviruses have also been reported to use heparan sulphate glycosaminoglycans (HSGs)
[4, 
5]
 as primary receptors and are able to bind heparan sulphate proteoglycans via a bridging 
interaction with factor X,
[6, 7]
 dipalmitoyl phosphatidylcholine
[8]
 or lactoferrin
[9]
. CD46 has 
been identified as the primary receptor for species B viruses (except 3 and 7 which use 
desmoglein-2)
[10-12]
 and sialic acid the primary receptor for most species D viruses 
responsible for epidemic keratoconjunctivitis.
[13-15]
 Following initial cell attachment, 
internalisation is mediated in most cases by penton base binding to DVE3 or DVE5 
integrins.
[16]
 Numerous human and non-human Ad serotypes have been developed for gene 
delivery and in addition many have been tropism modified either genetically or chemically 
to improve gene delivery to target cells.
[17]
 Given the array of different viruses and cellular 
receptors, highly sensitive techniques to track virus and define virus-cell binding 
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interactions are valuable in understanding the natural viral lifecycle as well as in the 
development of new gene delivery vectors.  
Quantum dots (Qdots) are nano scale particles which can be used as fluorescent labels of 
biological molecules.
[18-20]
 They are composed of an inorganic core, which determines the 
fluorescent properties, surrounded by a shell of zinc sulphide to improve optical properties 
and prevent leaching and further encompassed by an organic layer allowing dispersion in 
water. Qdots have a blue shifted excitation profile, high quantum yield, discrete emission 
spectrum (determined by the size of the inorganic core) and are highly photo-stable,
[21]
 
features which offer significant advantages over organic fluorophores. Binding of Qdots to 
the recipient biological molecule first requires surface functionalisation of both the Qdot and 
the target molecule. In the context of labelling adenovirus, chemical surface 
functionalisation may provide advantages over genetic functionalisation, as genetically 
modified capsid components can be detrimental to virus fitness and genetic stability. The 
minor capsid protein pIX has been identified as an attractive target for genetic 
modification
[22]
, however both replication deficient
[23]
 and replication competent viruses 
bearing pIX-GFP fusions have significantly compromised fitness.
[24, 25]
 As an alternative 
method, Ad has been chemically surface modified with fluorophores such as Texas Red 
(TR).
[26]
 TR-succidmyl esters react with free amino groups on the surface of the virus 
capsid, covalently attaching the fluorophore to purified virus in a simple one step reaction. 
Texas Red labelled virus has been used to analyse virus binding and sub-cellular trafficking, 
however this is a process which requires complex image acquisition, analysis and suffers 
from photo-bleaching and low levels of sensitivity. Qdots have been used to label a range of 
different viruses
[27-38]
 including enveloped viruses such as human T cell leukaemia virus 
(HTLV)
[39]
 and human immunodeficiency virus (HIV),
[40]
 non-enveloped viruses such as 
adeno-associated virus (AAV)
[41]
 and have been incorporated into SV40 pseudoparticles
[42]
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Furthermore, Qdots have been recently utilised as highly sensitive reagents for the detection 
of medically relevant pathogens
[43-47]
 including hepatitis B virus
[48, 49]
, Epstein-Barr virus
[50-
52]
 and picornaviruses,
[53, 54]
 and have therefore been suggested as potential tools in medical 
diagnosis.  
 
In this study we describe a method to label adenovirus with streptavidin functionalised 
Qdots following chemical biotinylation of the virion surface proteins. The technique is 
rapid, reproducible, and can be applied to different serotypes and to tropism modified 
vectors. Labelling does not interfere with virus fitness and its application in studying virus 
internalisation and trafficking is demonstrated using imaging cytometry.  
 
In order to determine the level of biotinylation compatible with retention of virus viability, a 
replication deficient Ad vector expressing eGFP (AdGFP)
[55]
 which had been purified 
[56]
 
was chemically biotinylated by incubation with increasing concentrations of N-
hydroxysuccinimido-biotin (NHS-biotin) (10, 100 and 1000 ȝJPO IRU 4 hours, room 
temperature) and free NHS-biotin removed by dialysis. Biotinylated virus was used to infect 
A549 cells (a cell line expressing high levels of CAR and permissive to Ad replication) at 
100 particles/cell and transduction assessed by GFP expression measured at 48 hours post 
infection by flow cytometry (Figure 1 (A)). The highest concentration (1 mg/ml) of biotin 
led to a complete block in virus transduction, presumably due to biotin interfering with 
fiber-CAR interactions, whilst at 100 ȝJPO WKHUH ZDV a 200-fold reduction in gene 
expression relative to unmodified virus. However at 10 Pg/ml, over 90% of transduction 
efficiency was retained. Concordant with this, virus particle to infectivity ratio of 10 Pg/ml 
biotinylated Ad was slightly higher than unmodified virus (15:1 vs 10:1, data not shown) but 
still within the acceptable range for adenoviral gene delivery vectors (typically between 10:1 
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and 100:1). Therefore for all subsequent work viruses were biotinylated with 10 µg/ml 
NHS-Biotin. 
 
Qdots display on their surface quadrivalent streptavidin and conjugating them directly to 
free biotinylated adenovirus in suspension led to virus aggregation and inactivation (data not 
shown); we therefore chose to bind virus to the cells prior to Qdot labelling. Furthermore, 
cells were pre-treated with excess biotin and streptavidin (as described in material and 
methods), to further reduce non-specific binding events. 
 
To label virus with Qdots, 10
5 
cells were incubated with increasing multiplicity of infection 
(MOI) of biotinylated AdGFP (bAdGFP) in the range 1 ± 1x105 particles/cell (90 minutes on 
ice), or mock infected and labelled with Qdots (1Pl of Qdot655-streptavidin conjugate/50 Pl, 
60 minutes on ice) and analysed by flow cytometry (Figure 1 (B)). As anticipated, Qdot 
fluorescence increased with increasing virus MOI, no appreciable fluorescence was detected 
with mock infected Qdot labelled cell above completely unlabelled cells.  
 
In order to compare the sensitivity of Qdot labelling with that of viral capsid bearing an 
organic fluorophore, the experiment was performed in parallel with a virus which encoded a 
pIX-GFP fusion protein (AdpIX-GFP):
[23]
 with each virus capsid containing up to 240 
copies of the pIX-GFP- fusion protein (Figure 1 (B)). While two viruses were of the same 
serotype and had comparable particle
[57]
 to infectivity ratio the GFP fluorescence of AdpIX-
GFP, was not readily detectable below 10
4
 particles/cells indicating the GFP tagging was in 
the order of 10-fold less sensitive than the Qdot labelling technique. Furthermore, the mean 
fluorescence yield for Qdot labelling was approximately 100-fold higher than that of GFP 
labelling at the same MOI (data not shown). To determine whether the labelling was bright 
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enough to detect single virus binding events by fluorescence microscopy, A549 cells were 
incubated with bAdGFP and Qdot655 labelled before being counterstained with DAPI and 
anti-CAR antibody (Figure 1 (C and D)). Fluorescent confocal microscopy revealed distinct 
foci consistent with individual virus binding events. 
 
To determine whether biotinylation or Qdot labelling adversely altered virus attachment, 
binding experiments were performed using A9-CAR cells
[58]
 (murine fibroblasts stably 
expressing human chromosome 21 which encodes human CAR) and parental A9 cells which 
are devoid of CAR, HSGs DQGĮV integrins and thus are totally refractory to wild type Ad5 
binding and infection.
[58]
 A9-CAR and A9 cells pre-treated with excess biotin and 
streptavidin were mixed at a ratio of 2:1 before virus and Qdot were bound on ice; cells were 
then stained for CAR expression and analysed by flow cytometry (Figure 2 (A)). Only CAR 
positive cells showed Qdot fluorescence after incubation with bAdGFP, whereas all cells 
incubated with AdGFP were negative for Qdot fluorescence. This confirms that the Qdot 
fluorescence is bAdGFP specific, that the biotinylation has not caused non-specific binding 
to a receptor negative cell line, and that the biotinylated virus can still bind to cells bearing 
an appropriate receptor. 
 
In order to determine whether biotinylation and labelling would compromise the ability of 
virus to internalise, A549 cells were incubated with bAdGFP and Qdots on ice to allow 
binding, before incubation at 37qC to allow internalisation. Cells were fixed in ice cold 
formaldehyde at regular time intervals up to 180 minutes and analysed by imaging 
cytometry (>4000 in focus single cell events per time point). For each cell analysed the 
internalised fluorescence was expressed relative to the total cell fluorescence and values 
normalised to the maximal internalisation achieved in the experiment (Figure 2 (B)). 
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bAdGFP internalisation was rapid, with 50% achieved within 5 minutes and the maximum 
(>95% internalised virus) achieved by 60 minutes. Figure 2 (C) shows the location of 
Qdot655 staining on representative images from the 0, 30, 60 and 180 minute timepoints. 
Qdot fluorescence was almost entirely associated with the plasma membrane at the 0 minute 
timepoint, after 30 minutes at 37qC virus fluorescence was entirely interior to the plasma 
membrane, at 60 minutes the fluorescence was mostly cytoplasmic and by 180 minutes there 
was distinct peri-nuclear accumulation of label, consistent with the ability of Qdot labelled 
virus to efficiently bind, internalise, and accumulate at the nuclear envelope. 
 
In order to demonstrate biotinylation/Qdot labelling can be applied to different adenovirus 
species; WTAd5 (species C) and WTAd11 (species B) were biotinylated and Qdot labelled. 
To test a tropism modified gene therapy vector, AdDM-1/E2F-RGD, an Ad5 derived 
oncolytic adenovirus vector genetically retargeted by incorporating the RGD ĮV integrin 
binding motif in the fiber HI loop, and an equivalent non-fiber modified vector AdDM-
1/E2F, were also tested. The efficiency of binding was determined on the human ovarian 
tumour cell line SKOV3 (which are low for CAR expression, but CD46 positive) and the 
matched cell line SKOV3-CAR
[59]
 (which stably expresses human CAR). bAd5, bAd11, 
bAdDM-1/E2F and bAdDM-1/E2F-RGD were titrated onto SKOV3 and SKOV3-CAR cells 
at 4qC, before Qdot655 labelling and analysis by flow cytometry (Figure 3). All four viruses 
displayed a dose dependent increase in fluorescence on both cell lines. Approximately 10-
fold more bAd5 was required on SKOV3 cells to achieve the same fluorescence as on 
SKOV3-CAR cells, indicating its high preference for CAR binding (Figure 3A). Both 
bAd11 and bAd5 show similar binding levels on SKOV3-CAR cells, both serotypes 
reaching saturation at 10
4 
particles/cell. However, bAd11 bound to SKOV3 and SKOV3-
CAR cells with equal efficiency as they both express its primary receptor CD46 (Figure 3B), 
8 
 
whereas Ad5 showed significantly lower levels of binding to SKOV3 than SKOV3-CAR. 
Introduction of the RGD integrin binding motif into Ad5 fiber has previously been reported 
to increase the efficiency of binding of Ad5 to CAR negative cells lines.
[60, 61]
 The binding 
of bAdDM-1/E2F (with WT Ad5 fiber) to SKOV3 and SKOV3-CAR cells showed a similar 
profile to that of bAd5 (Figure 3C), with significantly less virus binding the SKOV3 cells 
than the SKOV-CAR cells. However, the RGD modified vector, bAdDM-1/E2F-RGD, 
demonstrated improved binding efficiency on the CAR negative SKOV3 cells with no 
significant differences in binding detected between the two cell lines irrespective of CAR 
expression (Figure 3D). 
 
The unique optical properties of Qdots
[18, 19]
 make them an attractive label for virus particle 
tracking. The brightness of emission permits detection of single virus particles using 
conventional fluorescent imaging technology such as confocal microscopy. Their inherent 
photo-stability facilitates data acquisition, with reduced photo-bleaching, and offers major 
advantages for virus tracking in live cells where the same cell comes under laser 
illumination multiple times or continuously.
[62]
 Kampani et al used Qdots to label HTLV
[39]
 
and demonstrated that increased virus binding was proportional to increased fluorescence, 
and therefore could be used for virus titration. Subsequently Joo et al applied a similar 
strategy to label lysates of HIV infected cells to analyse virus binding to lymphocytes,
[40]
 
and SV40-Qdot hybrid pseudoparticles have been constructed allowing for imaging of virus 
binding and internalisation by time lapse confocal microscopy.
[42]
 Since these initial studies 
Qdots have been used to label a number of enveloped and non-enveloped viruses,
[29, 31, 37, 41, 
63]
 allowing for single virus tracking of baculovirus,
[27, 30]
 influenza A virus
[32, 64]
 and 
hematopoietic necrosis virus
[35]
 which has facilitated a more detailed characterisation of 
viral endocytitic pathways.  
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Here we show for the first time Qdots can be conjugated to intact adenoviruses without a 
detrimental impact or modification of viral function, tropism, internalisation or transduction 
efficacy. Furthermore, this quantum dot Ad labelling technique was at least 10-times more 
sensitive than an Ad5 displaying surface eGFP, genetically fused to the viral capsid. In 
combination with imaging cytometry analysis, the Qdot labelling strategy described here can 
be easily used to visualise and accurately measure virus internalisation.  
 
Adenovirus internalisation and sub-cellular trafficking has previously been studied using 
both transmission electron microscopy (TEM)
[65]
 and fluorescent labelling with texas red.
[26]
 
TEM is a relatively laborious and time consuming technique, with analysis usually 
performed on a small number of cells. Similarly, the image acquisition and analysis for 
Texas Red labelled Ad involves Fourier transformation of multiple Z sections of individual 
cells taken with a CCD camera under high magnification and as a consequence analysis is 
limited to a relatively small number of cells. Imaging cytometric analysis is an emerging 
technology which combines the high throughput and statistical rigour of flow cytometry 
with the locational information provided by fluorescent microscopy.
[66]
 Here we were able to 
measure virus internalisation rapidly and reproducibly, acquiring and analysing data for 
thousands of cells at multiple time points. Internalisation of virus pre-bound to A549 cells 
was rapid, with greater than 50% of virus internalised within 5 minutes. By 180 minutes 
post-infection, much of the Qdot fluorescence was concentrated around the nucleus which is 
similar to the rate at which virus escapes the endosome and traffics to the nucleus,
[67-72]
 
suggesting Qdots remain associated with the partially uncoated virus capsids. The Qdot 
labelling technique did not reduce virus infectivity as measured by plaque assay or the 
ability of transgene containing vectors to transduce target cell lines and so while 
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uncharacterised effects of Qdots on cellular uptake pathways cannot be ruled out, the normal 
productive viral pathways appears to be largely unperturbed. Whilst the number of Qdots 
bound to each viral particle is unclear from the data presented we anticipate based on the 
average diameter of an Adenovirus type 5 capsid (approximately 90nm) and the average 
diameter of the quantum dots used (approximately 15nm), a maximum Qdot to virus ratio of 
~4:1. However it is important to note that for quantification, the binding should be uniform 
across each viral capsid and thus total mean fluorescence is proportional to amount of bound 
virus. 
 
The Qdot labelling method we describe here is of value for the study of virus entry and sub-
cellular localisation as well as for characterisation of the numerous tropism-modified gene 
delivery vectors under development. We demonstrate that the Qdot labelling strategy works 
equally well for Ad5 and Ad11, which use different cellular receptors (CAR and CD46, 
respectively), and for an Ad5 based gene therapy vector with the RGD integrin binding 
motif inserted in the HI loop of the fiber protein. All viruses bound to SKOV3-CAR cells 
with very similar efficiencies, whilst, as would be expected the WTAd5 fiber-containing 
viruses bound to SKOV3 (CAR negative) cells with a 10-fold reduced efficiency. It has 
previously been reported that insertion of an RGD motif within the HI loop of Ad5 vectors 
increases the binding to integrin positive human cells,
[60]
 including SKOV3 cells,
[61]
 
primarily through interaction with DVE3.[73] Consistent with this observation, AdDM-1/E2F-
RGD bound CAR negative SKOV3 cells with only a slightly reduced (non-significant) 
efficiency relative to the CAR positive equivalent (SKOV-CAR) and with greater efficiency 
than the WT Ad5 fiber containing viruses (AdDM-1/E2F and WTAd5). Ad11 bound both 
SKOV3 and SKOV3-CAR cells with equal efficiency, consistent with their equal expression 
of CD46.  
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In conclusion, we demonstrate that quantum dot labelling is a sensitive technique to quantify 
cellular binding and uptake of adenovirus. This method will be useful for assessing the 
interaction of tropism modified gene therapy vectors with target and non-target cells to 
identify low level binding events. Furthermore, when in combination with imaging 
cytometry, Qdot labelling provides a simple method for studying viral internalisation and 
intra-cellular trafficking. 
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Figure 1 Quantum dot labelled biotinylated adenovirus. (A) Transduction of A549 cells 
with 100 particles/cell of biotinylated AdGFP as determined by flow cytometry 48 hours 
post infection (B) Comparison of Qdot655 labelled bAdGFP to pIX-GFP labelled AdpIX-
GFP. A549 cells were infected with appropriate viruses at stated MOI (60 minutes, 4qC) and 
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Qdot655 added. Cells were analysed by flow cytometry to determine the percentage of cells 
with detectable GFP signal or Qdot655 signal in comparison to mock infected cells (data 
shows mean, n=3, +/- S.D.). (C and D) Representative confocal images of bAdGFP binding 
to A549 cells at 10
3
 particles/cell showing a single confocal Z-section detected with anti-
mouse Qdot525 secondary antibody co-stained with DAPI and anti-CAR RmCb (C) a 
composite stack of 10 optical Z-slices of a single cell counter-stained with DAPI (D). 
Images were taken with a 63X lens with 1.5X digital zoom.  
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Figure 2 CAR specificity and internalisation of QdotbAd5 (A) A9-CAR and parental A9 
cells were mixed at ratio of 2:1 and infected with Ad5 or bAd5 (60 minutes, 4qC, MOI 104 
particles/cell), before addition of Qdot655 and co-staining with anti-CAR and anti-mouse 
FITC secondary, cells were analysed by flow cytometry. (B and C) A549 cells were infected 
with bAd5 (60 minutes, 4qC, MOI 104 particles/cell), cells were incubated at 37qC for the 
specified times before fixing in ice cold formaldehyde, counter-staining with DAPI and 
analysed using an Amnis image stream 100. (B) Normalised surface internalisation. Data 
shows mean, n=3, +/- S.D. (C) Representative images showing brightfield, brightfield 
merged with bAd5-Qdot655 fluorescence and bAd-Qdot655 fluorescence merged with 
DAPI staining. 
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Figure 3. Qdot labelling of different Ad serotypes and tropism modified gene therapy 
vectors. Biotinylated (A) Ad5; (B) Ad11; (C) AdDM-1/E2F and (D) AdDM-1/E2F-RGD 
were bound to SKOV3 and SKOV3-CAR cells (on ice at given MOIs) before incubation 
with Qdot655 and analysis by flow cytometry (data shows mean, n=3, +/- S.D., * indicate 
significant differences between binding to SKOV-CAR and SKOV cells (Paired T Test)). 
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Experimental Section 
Viruses and Biotinylation 
AdGFP ('E1/E3 CMVIEGFP) is a replication defective Ad5 vector, encoding eGFP under 
control of the CMV immediate early promoter. Wildtype (WT) Ad11 was a kind gift from 
Professor Gavin Wilkinson (University of Cardiff). AdpIX-GFP was a kind gift from Dr 
Robin Parks (Ottawa Health Research Institute) and expresses a pIX-GFP fusion protein for 
fluorescent tracking. AdDM-1/E2F and AdDM-1/E2F-RGD are Ad5 based gene therapy 
vectors with the E1A promoter replaced by an E2F promoter/Kozak sequence downstream 
of a SV40 late poly(A) signal and a DM-1 insulator element (generated using plasmids 
kindly donated by Dr Alemany). Both viruses have a splice acceptor-linked eGFP gene 
inserted downstream of the protein IV (fiber) gene. AdDM-1/E2F-RGD contains a cyclic 
RGD sequence inserted into the HI loop of the fibre gene. AdGFP and AdpIX-GFP were 
grown in HEK293 cells whilst Ad5, Ad11, AdDM-1/E2F and AdDM-1E2F-RGD were 
JURZQ LQ $ FHOOV DOO JURZQ LQ 'XOEHFFR¶V 0RGLILHG (DJOH 0HGLXP '0(0
supplemented with 2% foetal calf serum (FCS) and GlutaMAX-1 (Invitrogen). All viruses 
were CsCl banded 
[56]
, titered by Picogreen assay for particle number and plaque assayed for 
infectivity before and after biotinylation. 
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For biotinylation, viruses were incubated with 10 Pg/ml NHS-Biotin (Sigma, Pool, UK) for 
4 hours at 20qC, unless otherwise stated. Excess NHS-Biotin was removed by dialysis 
against storage buffer (PBS, 10% glycerol (v/v), 500 PM MgCl2, 900 PM CaCl2) for 16 
hours at 4°C.  
 
Cell Preparation and Qdot Labelling 
A549, HEK293 and SKOV3 cells were obtained from the ATCC (Manassas, VA, USA). A9 
and A9-CAR cells were kindly donated by Dr Paul Freimuth (Brookhaven National 
Laboratory).
[58]
 SKOV-CAR cells were generated by transfection with the pXLNC-hCAR 
retrovirus as has been described previously.
[59]
 All cells were grown in DMEM 
supplemented with 10% foetal calf serum and GlutaMAX-1 (Invitrogen).  
For virus Qdot labelling, cells were trypsinised, trypsin neutralised by addition of excess full 
growth media, washed (PBS supplemented with 5% FCS) before the cell suspension was 
incubated with excess streptavidin, washed and incubated with excess biotin (Endogenous 
Biotin Blocking kit, Invitrogen, Paisley, UK). Cells were washed and each sample 
resuspended in 50Pl PBS supplemented with 5% FCS. Virus was bound to cells on ice for 
90 minutes, washed, re-suspended in 50 Pl PBS + 5% FCS containing 1 Pl of Qdot655-
Streptavidin conjugate (Invitrogen). Cells were incubated for 30 minutes on ice, washed and 
either analysed directly or co-stained with antibodies.  
 
Confocal Microscopy 
For confocal microscopy cells were grown on glass cover slips and prepared as above  
Cells were grown on cover slips (Fisher Scientific, Loughborough, UK) and prepared as 
above but without cell detachment by trypsinisation. Cells were stained with 5 Pg anti-CAR 
mAb RmCb (Cancer Research UK, UK) (20 minutes at 4qC), visualised with secondary anti-
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mouse Qdot525 (Invitrogen) and counter-stained with 0.5 Pg/ml DAPI (Sigma) (10 minutes 
at 4qC). Cells were mounted in Clarion Mounting Media (Sigma) and visualised using a 
Zeiss LSM510 meta confocal microscope. 
 
Flow Cytometry  
Where indicated cells in suspension were co-stained with 5 Pg anti-CAR mAb RmCb (20 
minutes at 4ºC) and detected using anti-mouse FITC secondary antibody (Invitrogen), 
IROORZLQJ PDQXIDFWXUHU¶V LQVWUXFWLRQV 'DWD ZDV FROOHFWHG XVLQJ D LSR II flow cytometer 
(BD Bioscience, San Jose, CA, USA) equipped using a 488nm laser 530/30nm band-pass 
filter (for FITC and GFP) and a 405nm laser 655/8nm band-pass filter (for Qdot655). Data 
was analysed using FlowJo software (Tree Star, Ashland, OR, USA). Statistical analysis was 
performed using Graph Pad Prism 6, using paired T Test and significance indicated as 
*P<0.05 , **P<0.005, ***P<0.0005. 
 
Imaging Cytometry 
Cells were suspended at 10
6
/ml in PBS + 5% FCS and data acquired using an Image Stream 
100 (Amnis, Seattle, US) with excitation at 488 nm (30 mW) and 405 nm (350 mW). 
Analysis was performed on single cell in focus events, identified by brightfield aspect 
ratio/area analysis and brightfield gradient RMS. To measure internalisation of Qdot 
labelled virus, default total cell masks were used to calculate total cell fluorescence and the 
area erode tool (brightfield channel) used to identify cell interiors. Internalisation index 
(defined by the percentage of interior cell fluorescence:total cell fluorescence) was 
calculated and expressed as percentage of maximum internalisation. Data analysis was 
performed with Ideas Software (Amnis, Seattle, WA, USA). 
 
 
